MX2013011314A - Tratamientos oftalmicos. - Google Patents
Tratamientos oftalmicos.Info
- Publication number
- MX2013011314A MX2013011314A MX2013011314A MX2013011314A MX2013011314A MX 2013011314 A MX2013011314 A MX 2013011314A MX 2013011314 A MX2013011314 A MX 2013011314A MX 2013011314 A MX2013011314 A MX 2013011314A MX 2013011314 A MX2013011314 A MX 2013011314A
- Authority
- MX
- Mexico
- Prior art keywords
- eye
- compositions
- pharmaceuticals
- tramadol
- analgesic
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229960004380 tramadol Drugs 0.000 abstract 3
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 abstract 3
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 2
- 230000000202 analgesic effect Effects 0.000 abstract 2
- 239000000314 lubricant Substances 0.000 abstract 2
- 229940005483 opioid analgesics Drugs 0.000 abstract 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 abstract 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 abstract 1
- 229920002125 Sokalan® Polymers 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000607 artificial tear Substances 0.000 abstract 1
- 208000010217 blepharitis Diseases 0.000 abstract 1
- 229960001631 carbomer Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940014041 hyaluronate Drugs 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229960003943 hypromellose Drugs 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con composiciones acuosas apropiadas para la administración tópica al ojo humano o animal, que contiene por lo menos un lubricante oftálmico polimérico, soluble en agua, tal como hialuronato, gel de carbómero o hipromelosa, junto con un analgésico soluble en agua. El analgésico puede ser un opioide, particularmente un opioide que tiene una afinidad para los receptores de 5-HT, tal como tramadol. Los niveles de tramadol típicos estarían en el intervalo de 0.5% a 1.0 p/v. Por ejemplo, las composiciones acuosas pueden usarse como lágrimas artificiales, y como lubricantes oftálmicos generales para el tratamiento de las afecciones, tales como ojo seco o blefaritis. Las composiciones adicionales combinan los agentes oftalmológicamente activos, tales como farmacéuticos, con opioides, en particular, tal como tramadol. Estas composiciones pueden usarse para tratar el ojo, mientras que reducen el dolor o el malestar que sería producido normalmente por la administración de estos farmacéuticos particulares al ojo, y aumentar la eficacia de los farmacéuticos. También se describen composiciones, que contienen opioides con actividad del receptor de 5-HT, los cuales son de uso general para aliviar el dolor en, o alrededor del ojo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1105732.0A GB201105732D0 (en) | 2011-04-05 | 2011-04-05 | Ophthalmic lubricants |
| GBGB1105731.2A GB201105731D0 (en) | 2011-04-05 | 2011-04-05 | Topical analgesics |
| PCT/GB2012/000330 WO2012136969A2 (en) | 2011-04-05 | 2012-04-05 | Ophthalmic treatments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013011314A true MX2013011314A (es) | 2014-03-27 |
| MX346312B MX346312B (es) | 2017-03-15 |
Family
ID=46086008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013011314A MX346312B (es) | 2011-04-05 | 2012-04-05 | Tratamientos oftalmicos. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20140088199A1 (es) |
| EP (2) | EP3799866A1 (es) |
| JP (2) | JP6148664B2 (es) |
| KR (2) | KR102165246B1 (es) |
| CN (2) | CN107982211A (es) |
| BR (1) | BR112013025493A2 (es) |
| CA (1) | CA2869280C (es) |
| ES (1) | ES2836808T3 (es) |
| HK (1) | HK1254720A1 (es) |
| MA (1) | MA35070B1 (es) |
| MX (1) | MX346312B (es) |
| WO (1) | WO2012136969A2 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX346312B (es) * | 2011-04-05 | 2017-03-15 | Optosolve Res & Dev Ltd | Tratamientos oftalmicos. |
| GB201217522D0 (en) * | 2012-10-01 | 2012-11-14 | Sharma Anant | ophthalmic therapy |
| US20160051526A1 (en) * | 2013-04-09 | 2016-02-25 | Cresset Biomolecular Discovery Ltd | The Local Treatment of Inflammatory Ophthalmic Disorders |
| ES2540151B1 (es) * | 2013-10-11 | 2016-02-29 | Farmalider S.A. | Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico |
| RU2549472C1 (ru) * | 2013-12-26 | 2015-04-27 | Илья Александрович Марков | Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз |
| WO2015106068A1 (en) * | 2014-01-10 | 2015-07-16 | Manistee Partners Llc | Treatment of migraines |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US20170232024A1 (en) | 2014-08-04 | 2017-08-17 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
| ES2936394T3 (es) * | 2015-02-24 | 2023-03-16 | Univ Illinois | Métodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos oculares |
| US9877964B2 (en) | 2015-02-24 | 2018-01-30 | Ocugen, Inc. | Methods and compositions for treating dry eye disease and other eye disorders |
| CN107847432A (zh) | 2015-05-29 | 2018-03-27 | 西德奈克西斯公司 | D2o稳定化的药物制剂 |
| ES2604816B1 (es) | 2015-09-09 | 2018-01-29 | Farmalider, S.A. | Composición farmacéutica de tramadol para uso oftálmico |
| PL3352766T3 (pl) * | 2015-09-24 | 2021-08-02 | Matrix Biology Institute | Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia |
| CN108697665A (zh) * | 2015-09-30 | 2018-10-23 | 乔治·爱德华·霍格 | 局部镇痛性疼痛缓解制剂、其制备和使用方法 |
| CN105232449B (zh) * | 2015-10-30 | 2019-04-09 | 上海昊海生物科技股份有限公司 | 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法 |
| EP3525885B1 (en) * | 2016-10-12 | 2022-01-26 | PS Therapy Ltd. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
| JP2020523406A (ja) | 2017-05-19 | 2020-08-06 | オクジェン アイエヌシー． | 眼科用組成物および使用方法 |
| JP2020523312A (ja) * | 2017-06-08 | 2020-08-06 | アイ・セラピーズ・エル・エル・シー | 低用量ブリモニジンの組み合わせおよびその使用 |
| US10835517B2 (en) * | 2017-12-15 | 2020-11-17 | Tarsus Pharmaceuticals, Inc. | Methods for treating ocular demodex using isoxazoline parasiticide formulations |
| WO2019122982A1 (en) | 2017-12-21 | 2019-06-27 | Grünenthal GmbH | Pharmaceutical combination in a bilayer tablet form comprising ketorolac tromethamine and tramadol hydrochloride, and its use in pain treatment |
| JP7370316B2 (ja) * | 2018-03-13 | 2023-10-27 | 参天製薬株式会社 | 点眼型洗眼薬用組成物 |
| FR3096890B1 (fr) | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| CA3143071A1 (en) | 2019-07-26 | 2021-02-04 | Proqr Therapeutics Ii B.V. | Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
| US11504269B2 (en) | 2019-11-19 | 2022-11-22 | Jennifer L. Fabian | Therapeutic bra |
| CN112007028A (zh) * | 2020-09-03 | 2020-12-01 | 北京博纳致恒科技有限责任公司 | 一种复合睫状肌松弛剂的人工泪液及用途 |
| US20240139136A1 (en) * | 2021-02-26 | 2024-05-02 | Vyluma Inc. | Methods and formulations for topical administration of gabapentinoids |
| WO2023285878A1 (en) * | 2021-07-13 | 2023-01-19 | Aviation-Ophthalmology | Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions |
| JPWO2024010039A1 (es) * | 2022-07-06 | 2024-01-11 | ||
| WO2024010040A1 (ja) * | 2022-07-06 | 2024-01-11 | ロート製薬株式会社 | 眼科組成物 |
| TW202408468A (zh) * | 2022-07-06 | 2024-03-01 | 日商樂敦製藥股份有限公司 | 眼科組成物 |
| JPWO2024010045A1 (es) * | 2022-07-06 | 2024-01-11 | ||
| WO2025146828A1 (ja) * | 2024-01-05 | 2025-07-10 | ロート製薬株式会社 | 眼科組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6384043B1 (en) | 1993-02-01 | 2002-05-07 | Gholam A. Peyman | Methods of alleviating pain sensations of the denuded eye with opioid analgesics |
| US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| DK0946157T3 (da) * | 1996-12-16 | 2002-07-08 | Alcon Lab Inc | Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte |
| US6174878B1 (en) * | 1999-08-31 | 2001-01-16 | Alcon Laboratories, Inc. | Topical use of kappa opioid agonists to treat otic pain |
| JP2004143157A (ja) * | 2002-10-01 | 2004-05-20 | Taisho Pharmaceut Co Ltd | 点眼剤 |
| US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
| EP1768650B1 (en) * | 2004-06-04 | 2008-07-16 | Camurus Ab | Liquid depot formulations |
| EP1611877A1 (en) * | 2004-06-28 | 2006-01-04 | Universidade de Coimbra | Method for preparing sustained-release therapeutic ophthalmic articles using compressed fluids for impregnation of drugs |
| WO2007057508A2 (en) * | 2005-11-18 | 2007-05-24 | Orion Corporation | Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol |
| WO2007087609A2 (en) * | 2006-01-25 | 2007-08-02 | Aciex, Inc. | Formulations and methods for treating dry eye |
| MX2009012645A (es) | 2007-05-24 | 2010-03-08 | Aciex Therapeutics Inc | Formulaciones y metodos para tratar el ojo seco. |
| EP2311446A1 (en) * | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
| MX346312B (es) * | 2011-04-05 | 2017-03-15 | Optosolve Res & Dev Ltd | Tratamientos oftalmicos. |
-
2012
- 2012-04-05 MX MX2013011314A patent/MX346312B/es active IP Right Grant
- 2012-04-05 MA MA36378A patent/MA35070B1/fr unknown
- 2012-04-05 EP EP20200285.3A patent/EP3799866A1/en active Pending
- 2012-04-05 JP JP2014503208A patent/JP6148664B2/ja active Active
- 2012-04-05 BR BR112013025493A patent/BR112013025493A2/pt not_active Application Discontinuation
- 2012-04-05 ES ES12721571T patent/ES2836808T3/es active Active
- 2012-04-05 WO PCT/GB2012/000330 patent/WO2012136969A2/en active Application Filing
- 2012-04-05 US US14/009,397 patent/US20140088199A1/en not_active Abandoned
- 2012-04-05 CN CN201711200533.4A patent/CN107982211A/zh active Pending
- 2012-04-05 EP EP12721571.3A patent/EP2694048B1/en active Active
- 2012-04-05 CA CA2869280A patent/CA2869280C/en active Active
- 2012-04-05 CN CN201280025096.6A patent/CN103687594A/zh active Pending
- 2012-04-05 KR KR1020187038197A patent/KR102165246B1/ko active Active
- 2012-04-05 KR KR1020137029016A patent/KR20140145948A/ko not_active Ceased
-
2016
- 2016-03-21 US US15/076,098 patent/US9913813B2/en active Active
-
2017
- 2017-03-07 JP JP2017043172A patent/JP6419876B2/ja active Active
-
2018
- 2018-10-26 HK HK18113731.7A patent/HK1254720A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160199320A1 (en) | 2016-07-14 |
| WO2012136969A3 (en) | 2013-01-03 |
| US20140088199A1 (en) | 2014-03-27 |
| MA35070B1 (fr) | 2014-04-03 |
| KR102165246B1 (ko) | 2020-10-13 |
| BR112013025493A2 (pt) | 2017-03-01 |
| MX346312B (es) | 2017-03-15 |
| EP3799866A1 (en) | 2021-04-07 |
| CN107982211A (zh) | 2018-05-04 |
| CA2869280C (en) | 2020-03-10 |
| EP2694048A2 (en) | 2014-02-12 |
| JP2017141243A (ja) | 2017-08-17 |
| HK1254720A1 (zh) | 2019-07-26 |
| KR20190004815A (ko) | 2019-01-14 |
| CN103687594A (zh) | 2014-03-26 |
| ES2836808T3 (es) | 2021-06-28 |
| CA2869280A1 (en) | 2012-10-11 |
| EP2694048B1 (en) | 2020-10-07 |
| US9913813B2 (en) | 2018-03-13 |
| WO2012136969A2 (en) | 2012-10-11 |
| JP2014513073A (ja) | 2014-05-29 |
| JP6419876B2 (ja) | 2018-11-07 |
| KR20140145948A (ko) | 2014-12-24 |
| JP6148664B2 (ja) | 2017-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX346312B (es) | Tratamientos oftalmicos. | |
| MX2020005217A (es) | Composicion oftalmica y dispositivo de administracion de la misma. | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| MX2020010907A (es) | Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central. | |
| BR112015001158A2 (pt) | formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia | |
| MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
| MX2021000376A (es) | Composiciones tópicas para el alivio del dolor. | |
| WO2011053801A3 (en) | Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye | |
| BR112012021905A2 (pt) | tratamento de nefrite lúpica usando laquinimod | |
| WO2012063237A3 (en) | Buffered ophthalmic compositions and methods of use thereof | |
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2024000828A (es) | Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis. | |
| RU2013141845A (ru) | Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа | |
| WO2009090624A3 (es) | Gel de quitosano para aplicaciones dermatológicas, proceso de obtención y uso del mismo | |
| MY147864A (en) | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| NZ704247A (en) | Compositions and treatment for eye diseases and disorders | |
| MX345042B (es) | Composiciones y métodos para tratamiento no quirúrgico de ptosis. | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| MX368880B (es) | Dexmedetomidina y medetomidina para su uso en el alivio de la aversión al ruido en un animal. | |
| MX342930B (es) | Composicion reticuladora mejorada, suministrada por iontoforesis, util para el tratamiento de queratocono. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: OPTOSOLVE RESEARCH & DEVELOPMENT LIMITED |
|
| FG | Grant or registration |